Progen Industries Ltd (PGLAF) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Progen Industries Ltd (PGLAF)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Henrik	5/15/2005 8:53:29 PM
	Read Replies (1) of 349

16/05/2005 Underwriting Agreement signed for Progen Listed Options (Warrants) Read this announcement and take note of the last paragraph about the Directors intending to exercise their listed and unlisted options/warrants. When the transaction is completed Progen should, after cost, have around A$23-24mil in the kitty going forward. This is an excellent cash position for any biotech company with drugs in development phase only. However, the shareprice may show some volatility once these options are exercised on 31 May and before any pharma deal is announced. Holding Progen shares. asx.com.au ssuerCode=pgl&timeFrameSearchType=D&releasedDuringCode=W&x=24&y=10

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next